Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.68 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.68 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.68 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.68 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.68 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.68 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602209 | 1.00 | MEN1 (0.68) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9602221 | 1.00 | MEN1 (0.68) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL16884437 | 0.87 | MEN1 (0.62) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603122 | 0.85 | MEN1 (0.64) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603127 | 0.85 | MEN1 (0.64) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603119 | 0.85 | MEN1 (0.64) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603114 | 0.83 | MEN1 (0.61) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603120 | 0.83 | MEN1 (0.61) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9603123 | 0.83 | MEN1 (0.61) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL9602239 | 0.82 | MEN1 (0.59) | MEN1KMT2AALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885ALDH1A1 528/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885ALDH1A1 528/4885 |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | MEN1 2077/4885KMT2A 1096/4885ALDH1A1 409/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.